From LabBoss.com http://www.labboss.com/viewnews.asp?nid=604
HOOD RIVER, Ore.--(BW HealthWire)--April 26,
2002--Parents of autistic children who suspect heavy
metal toxicity as a contributor to their child's
condition may find a nontoxic oral clathration agent
will perform as well as or better than typically used
chelating agents, according to a report in the
nationally respected consumer journal, The Doctors'
Prescription for Healthy Living.
The report details the experience of a Troy,
Michigan, couple whose child was diagnosed with autism
that may have resulted from or been exacerbated by such
toxicity. The couple notes that the oral clathration
agent proved to be as more effective than their son's
DMSA/DMPS treatments, yet without side effects.
Autistic children may be prescribed
dimercaptosuccinic acid (DMSA) or dimercaptopropane
sulfonate (DMPS) if heavy metal toxicity is suspected.
However, the oral clathration agent increased their
child's heavy metal output by two to three times (as
measured by urinalysis). The couple is quoted as telling
the publication, "In two months, we had the same
benefits with PCA-Rx and ionic minerals as using DMSA
for an entire year. Also, unlike DMSA, PCA-Rx will not
chelate beneficial minerals, one reason it is less
stressful to the child's body."
"This information is important to parents of
autistic children," notes publisher and editor
David Steinman. "Many of the treatments afforded to
children have some toxicity associated with them and
stress the child. Based on our current report and past
reports, we believe that oral clathration is certainly
an option that parents should know about."
Steinman notes that while conventional oral chelation
therapy may be described as one dimensional, oral
clathration is a three-dimensional process. In this
case, specifically sequenced glycoproteins and peptides
form a lattice or inclusion complex and multiple
receptor sites attach to a toxic molecule with
irreversible bonds, literally wrapping around the toxic
substance to prevent additional reactions with tissues
or organs as it is eliminated from the body.
Unlike the ionic bond utilized to transport metals
from the body with chelation, clathration utilizes
ionic, covalent and hydrogen bonds. Not one but three
major types of bonds at multiple points are created.
"The product, PCA-Rx, has a very high bonding
affinity for heavy metals," notes Steinman.
"Most toxins or heavy metals that attach to cell
receptors do so in a manner that is competitively
reversible, so if molecules like those in PCA-Rx come
along with greater affinity, the toxins can be dislodged
from the receptors. Because of the formula's tremendous
affinity for heavy metals, this is an improvement over
chelation therapy, which has a much more difficult time
removing heavy metals from cell receptors."
"We want parents of autistic children and groups
dedicated to helping such children and adults to know
about oral clathration because it is a viable and
important option," adds Steinman.
He adds, "Few proven treatments are available to
autistic children. What we do know is that heavy metal
toxicity may sometimes be part of the pathology. Testing
for heavy metal burden is essential. PCA-Rx has been
successfully used with autistic children to safely
accelerate detoxification. While additional clinical
studies are desired, we know that PCA-Rx is safe and
efficacious. It is an important healing pathway that
parents of autistic children should know about."
Steinman, a nationally recognized consumer advocate,
is available for interviews and may be contacted at
CONTACT: ASN(TM)/MAXAM(TM) Nutraceutics(TM)
Lisa Williams, 541/387-4500